Actions for Gilead Sciences and Sovaldi [electronic resource] : the cost of a cure (B)

Email RIS file
Bookmark
Report an Issue

Gilead Sciences and Sovaldi [electronic resource] : the cost of a cure (B) / Benjamin Budish, Chase Lane, Richard Zaleski, James S. O'Rourke

Author
Budish, Benjamin
Published
London : SAGE Publications Ltd, 2017.
Physical Description
1 online resource
Additional Creators
Lane, Chase, Zaleski, Richard, and O'Rourke, James S., 1946-
Access Online

Availability

I Want It
I Want It

Finding items...

Series
Restrictions on Access
License restrictions may limit access.
Summary
Gilead Sciences hepatitis C drug, Sovaldi, proved more effective than the competition and was priced in line with market conditions. However, extremely high cost and large patient population captured the attention of the media, the public, NGOs, and even the government. The controversy deepened when the company revealed the cost in developing countries would be roughly 1% of the cost in the U.S.
Subject(s)
Genre(s)
ISBN
9781526403124 (ebook)
Note
Originally published in Budish, B., Lane, C., Zaleski, R., & ORourke, J. S. (2014). Gilead Sciences and Sovaldi: The cost of a cure (B). 14-10 (B). Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.
View MARC record | catkey: 31196505